A new paper published in Cell Reports discovered splicing deregulations that could cause therapeutic vulnerability in pediatric acute myeloid leukemia (pAML). UC San Diego scientists and physicians used various analytical and gene-splicing tools to uncover new information on this form of childhood blood cancer. While pAML is a confounding disease for clinicians and researchers, the team hypothesized that the cancer’s drivers occurred within transcriptomic and epitranscriptomic processes.

Pediatric acute myeloid leukemia is a type of leukemia in which the bone marrow makes many abnormal blood cells. In healthy children, bone marrow makes blood stem cells that become different types of mature blood cells over time. Myeloid stem cells may become red blood cells that carry oxygen to tissues; granulocytes, which are white blood cells that help fight infections; or platelets that form clots to stop bleeding. Lymphoid stem cells become lymphocytes, which are white blood cells that are part of the immune system.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

The team identified deregulations in splicing, an essential part of decoding gene instructions into proteins. This led to a therapeutic vulnerability to a small molecule splicing inhibitor called Rebecsinib. The researchers reported last month that Rebecsinib, an experimental drug, reversed malignant hyper-editing by an inflammation-induced protein known as ADAR1 p150, which promotes immune silencing, metastasis, and therapeutic resistance in 20 different cancer types, including leukemia.

The team’s findings suggest a new approach to detecting and targeting therapy-resistant leukemia stem cells in pediatric AML and other cancer stem cells that become recalcitrant to treatment due to this splicing deregulation.

The exact cause of pAML is unknown, but children with certain genetic disorders, such as Down syndrome or Fanconi anemia, have been identified as risk factors. The discovery of the deregulation in splicing and its therapeutic vulnerability to Rebecsinib represents a potentially clinically tractable strategy for pAML therapy. This breakthrough could lead to new treatments and improved outcomes for children with the disease.